Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics
This article was originally published in The Gray Sheet
Executive SummaryCentocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.